S389 Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection for Non-Pedunculated 20-40 mm Colonic Lesions: An Enhanced Markov Model Accounting for Recurrence, Recovery, and Adverse Events

Introduction: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are standard approaches for 20–40 mm nonpedunculated colorectal polyps. While ESD achieves higher en bloc and R0 resection rates, it is technically demanding and resource intensive. We developed an enhanced Markov model comparing EMR and ESD over 5 years, incorporating recurrence, adverse events, surveillance burden, procedure time, and productivity loss. Methods: A 5-state Markov model (Initial, En Bloc, Recurrence, Surgery, Death) was applied to a hypothetical cohort of 1,000 patients over 5 1-year cycles. Transition probabilities, recurrence rates, and adverse event frequencies were derived from published literature. Perforation and bleeding rates were assigned to both strategies (EMR: 2%/6%; ESD: 5%/4%). Utility decrements were applied for post-procedure recovery, complications, and surveillance. Costs included procedural fees, operating room time ($10/min), and productivity loss ($400/day). Outcomes were expressed as total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) at a 3% discount rate. Results: Over the 5-year simulation period, the EMR strategy resulted in 3,628 total QALYs at a cost of $25.3 million, while the ESD strategy produced 3,847 QALYs at $39.4 million. This yielded an incremental gain of 218 QALYs at an additional $14.2 million, resulting in an ICER of $64,860 per QALY gained. The model incorporated multiple real-world factors. Adverse event rates (EMR: 2% perforation, 6% bleeding; ESD: 5% perforation, 4% bleeding) increased procedural costs and modestly reduced QALYs. Surveillance burden was higher after EMR due to more frequent recurrence, adding both cost and quality-of-life penalties. Recovery-related productivity loss was incorporated, with EMR incurring 1 day off work, ESD 3 days, and surgery 21 days. Finally, differences in recurrence were used to simulate R0 resection vs positive margins—ESD's higher en bloc and curative resection rates translated to fewer recurrences and better long-term QALYs. These enhancements provide a realistic and comprehensive view of downstream outcomes and resource needs. Conclusion: ESD provides superior long-term outcomes compared to EMR for large nonpedunculated colonic polyps and remains cost-effective under standard willingness-to-pay thresholds. These findings support investment in advanced endoscopic training and procedural planning for optimized outcomes in colorectal neoplasia management.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001129016.17973.ed
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S389 Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection for Non-Pedunculated 20-40 mm Colonic Lesions: An Enhanced Markov Model Accounting for Recurrence, Recovery, and Adverse Events

Shiza Sarfraz, Rami Basmaci, Dushyant Singh Dahiya, Hassam Ali et al.
The American Journal of Gastroenterology
Gastric Cancer Management and Outcomes
article

S389 Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection for Non-Pedunculated 20-40 mm Colonic Lesions: An Enhanced Markov Model Accounting for Recurrence, Recovery, and Adverse Events

Shiza Sarfraz, Rami Basmaci, Dushyant Singh Dahiya, Hassam Ali, Farah Fleti, Umar Hayat, Eslam Ali
article en

Abstract

Introduction: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are standard approaches for 20–40 mm nonpedunculated colorectal polyps. While ESD achieves higher en bloc and R0 resection rates, it is technically demanding and resource intensive. We developed an enhanced Markov model comparing EMR and ESD over 5 years, incorporating recurrence, adverse events, surveillance burden, procedure time, and productivity loss. Methods: A 5-state Markov model (Initial, En Bloc, Recurrence, Surgery, Death) was applied to a hypothetical cohort of 1,000 patients over 5 1-year cycles. Transition probabilities, recurrence rates, and adverse event frequencies were derived from published literature. Perforation and bleeding rates were assigned to both strategies (EMR: 2%/6%; ESD: 5%/4%). Utility decrements were applied for post-procedure recovery, complications, and surveillance. Costs included procedural fees, operating room time ($10/min), and productivity loss ($400/day). Outcomes were expressed as total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) at a 3% discount rate. Results: Over the 5-year simulation period, the EMR strategy resulted in 3,628 total QALYs at a cost of $25.3 million, while the ESD strategy produced 3,847 QALYs at $39.4 million. This yielded an incremental gain of 218 QALYs at an additional $14.2 million, resulting in an ICER of $64,860 per QALY gained. The model incorporated multiple real-world factors. Adverse event rates (EMR: 2% perforation, 6% bleeding; ESD: 5% perforation, 4% bleeding) increased procedural costs and modestly reduced QALYs. Surveillance burden was higher after EMR due to more frequent recurrence, adding both cost and quality-of-life penalties. Recovery-related productivity loss was incorporated, with EMR incurring 1 day off work, ESD 3 days, and surgery 21 days. Finally, differences in recurrence were used to simulate R0 resection vs positive margins—ESD's higher en bloc and curative resection rates translated to fewer recurrences and better long-term QALYs. These enhancements provide a realistic and comprehensive view of downstream outcomes and resource needs. Conclusion: ESD provides superior long-term outcomes compared to EMR for large nonpedunculated colonic polyps and remains cost-effective under standard willingness-to-pay thresholds. These findings support investment in advanced endoscopic training and procedural planning for optimized outcomes in colorectal neoplasia management.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 56%
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.